FAROTTI, LUCIA
 Distribuzione geografica
Continente #
NA - Nord America 646
EU - Europa 339
AS - Asia 200
Totale 1.185
Nazione #
US - Stati Uniti d'America 646
IE - Irlanda 140
VN - Vietnam 75
IT - Italia 73
HK - Hong Kong 46
CN - Cina 36
SG - Singapore 36
RO - Romania 23
RU - Federazione Russa 23
UA - Ucraina 14
FI - Finlandia 13
FR - Francia 12
DE - Germania 10
SE - Svezia 9
BE - Belgio 5
GB - Regno Unito 5
KR - Corea 4
CZ - Repubblica Ceca 3
PL - Polonia 3
CH - Svizzera 2
NL - Olanda 2
TR - Turchia 2
JP - Giappone 1
LU - Lussemburgo 1
RS - Serbia 1
Totale 1.185
Città #
Chandler 210
Dublin 140
Dong Ket 75
San Mateo 51
Hong Kong 46
Altamura 37
Wilmington 32
Medford 29
Princeton 28
Des Moines 27
Lawrence 27
Perugia 23
Ann Arbor 22
Singapore 20
Timisoara 18
Beijing 17
Andover 14
Falls Church 10
Los Angeles 10
Saint Petersburg 10
Norwalk 7
Brussels 5
Bucharest 5
San Paolo di Civitate 5
Helsinki 4
Redwood City 4
Seoul 4
Boardman 3
Lappeenranta 3
Den Haag 2
Fairfield 2
Fremont 2
Izmir 2
New York 2
Paris 2
Bologna 1
Denver 1
Edinburgh 1
Falkenstein 1
Houston 1
Kiev 1
Ludwigshafen 1
Luxembourg 1
Moscow 1
Nis 1
Olomouc 1
Queens 1
Radeberg 1
Redmond 1
Rome 1
San Severo 1
Totale 914
Nome #
The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease 75
Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI) 70
Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology 65
Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis 64
Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study 58
Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms 51
Unraveling Pathophysiological Mechanisms of Parkinson’s Disease: Contribution of CSF Biomarkers 50
Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study 49
Biomarker-based signature of alzheimer’s disease in pre-MCI individuals 48
Differential diagnosis between Alzheimer's disease and other dementias: Role of cerebrospinal fluid biomarkers 44
Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases 44
Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine 43
Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes 43
Two-year longitudinal monitoring of amnestic mild cognitive impairment patients with prodromal Alzheimer's disease using topographical biomarkers derived from functional magnetic resonance imaging and electroencephalographic activity 41
Parkinson's and Lewy body dementia CSF biomarkers 38
Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker 38
Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study 36
Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: A 'European ADNI study' 36
Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study 36
Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms 36
White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers 36
Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders 35
Late-Onset Epilepsy With Unknown Etiology: A Pilot Study on Neuropsychological Profile, Cerebrospinal Fluid Biomarkers, and Quantitative EEG Characteristics 35
Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s disease 34
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease. 33
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry 33
Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study 30
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores 28
null 13
Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores 9
Totale 1.251
Categoria #
all - tutte 5.614
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.614


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202050 1 0 0 0 0 1 11 3 11 10 13 0
2020/2021186 2 1 7 6 64 2 5 4 1 4 2 88
2021/2022223 4 38 0 2 11 8 7 58 8 17 35 35
2022/2023596 33 110 7 71 40 75 0 30 202 2 19 7
2023/2024169 14 21 9 7 2 0 42 3 4 15 31 21
2024/20254 4 0 0 0 0 0 0 0 0 0 0 0
Totale 1.251